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The development of the vascular system begins with the formation of hemangioblastic cells, hemangioblasts, which organize
in blood islands in the yolk sac. The hemangioblasts diﬀerentiate into hematopoietic and angioblastic cells. Subsequently, the
hematopoietic line will generate blood cells, whereas the angioblastic cells will give rise to vascular endothelial cells (ECs). In
response to speciﬁc molecular and hemodynamic stimuli, ECs will acquire either arterial or venous identity. Recruitment towards
the endothelial tubes and subsequent diﬀerentiation of pericyte and/or vascular smooth muscle cells (vSMCs) takes place and
the mature vessel is formed. The Notch signaling pathway is required for determining the arterial program of both endothelial
and smooth muscle cells; however, it is simultaneously involved in the generation of hematopoietic stem cells (HSCs), which will
give rise to hematopoietic cells. Notch signaling also regulates the function of endothelial progenitor cells (EPCs), which are bone-
marrow-derivedcellsabletodiﬀerentiateintoECsandwhichcouldbeconsideredtheadultcorrelateoftheangioblast.Inaddition,
Notch signaling has been reported to control sprouting angiogenesis during blood vessels formation in the adult. In this paper we
discuss the physiological role of Notch in vascular development, providing an overview on the involvement of Notch in vascular
biology from hematopoietic stem cell to adaptive neovascularization in the adult.
1.Introduction
During embryogenesis, the earliest stages of vascular devel-
opment occur when hematopoietic cell and ECs precursors,
hemangioblasts, migrate and diﬀerentiate into blood islands.
Once hemangioblasts organize in blood islands, they fuse to
form the primitive capillary plexus in a process termed vas-
culogenesis [1, 2]. The cells surrounding the islands will sub-
sequentlydiﬀerentiateintoECs,whilethoseinthecentrewill
form hematopoietic precursors.
The newly formed plexuses grow as a result of angiogen-
esis, that is, vascular sprouting and tube formation by single
ECs within a preexisting capillary plexus, or by intussuscep-
tions, that is, a longitudinal division of existing vessels,
involving reorganization of the interendothelial cell junc-
tions, central perforation of the bilayer, followed by intersti-
tial pillar core formation [3, 4]. Subsequently, endothelial
cells become surrounded by pericytes and myoﬁbroblasts the
newly forming vessel is stabilized into an arteriole (arterio-
genesis).
During the process of arteriogenesis, multiple layers of
pericytes or SMCs to, respectively, generate small or large
vessels of the vascular system cover the formed channel of
endothelial cells. A large number of intercellular signaling
pathways are implicated in these processes. The analysis of
diﬀerent mouse embryos with targeted mutation of Notch
revealed the importance of Notch in all these processes of
vascular development [2].
This paper assesses the current knowledge of Notch
functionincontrollingcellfateduringvasculardevelopment.
In particular, we discuss the role of Notch in the formation
of hematopoietic cells in the embryo and HSCs self-renewal
in the adult. We also review the potential eﬀect of Notch
in EPCs activity and its implication for neovascularization.2 Stem Cells International
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Figure 1: Mammalian cells are equipped with 4 Notch receptors (Notch1-4) and ﬁve ligands (Jag1,2 and Dll1,3,4). Notch signaling is
triggered upon receptor-ligand interaction, which induces two sequential proteolytic cleavages. The ﬁrst cleavage, in the extracellular
domain, is catalyzed by ADAM metalloproteinases, and the second, within the membrane domain, is facilitated by the γ-secretase complex.
This second cleavage allows the release and translocation of the Notch intracellular domain (NICD) to the nucleus. Binding of NICD
to cotranscription factor RBPjk leads to transcriptional activation of the Notch target genes HES and HERP/HEY by displacement of a
corepressor (CoR) and recruitment of the coactivator, mastermind-like protein (MAML1).
Finally, we report on the function of Notch in sprouting an-
giogenesisandarterialcellfatespeciﬁcationofbothendothe-




The Notch pathway is an evolutionary highly conserved sig-
naling system. Four diﬀerent Notch receptors, Notch-1 to -4,
and ﬁve ligands, Delta-like (Dll)-1, -3, -4, and Jagged (JAG)-
1,-2,havebeenidentiﬁedinvertebrates.TheNotchmembers
are single-pass transmembrane protein. Notch receptors are
synthesized as single-chain precursors that, after glycosy-
lation by protein O-fucosyl transferase (POFUT1) in the
endoplasmic reticulum, are processed into noncovalently
linked Notch extracellular (NECD) and intracellular (NICD)
domains in the trans-Golgi [5–7]. The receptor-ligand
interaction induces two proteolytic cleavages of the receptor.
The ﬁrst is mediated by extracellular proteases, known as
A disintegrin and metalloprotease (ADAM), TNF-α con-
verting enzyme (TACE) or kuzbanian. Subsequently, the γ-
secretase complex mediates a second proteolytic cleavage
that releases the Notch intracellular domain (NICD) from
the membrane. Next, the NICD translocates to the nucleus,
where it associates with the DNA binding protein RBP-Jk
(also named CSL after mammal CBF1, Drosophila Su(H),
and Caenorhabditis elegans LAG-1) and its coactivator
Mastermind (Mam) to initiate the transcription of its down-
stream targets, such as the basic helix-loop-helix proteins
hairy/enhancerofsplit(HES)andhairy-relatedtranscription
factors(HRT,HERP,HEY)[7–11],whichinturnregulatethe
transcription of downstream genes (Figure 1).
The importance of Notch in vascular development has
been addressed in vivo by gene targeting and mutation stud-
ies.KnockoutmiceofseveralcomponentsoftheNotchpath-
way, such as Notch1, Notch1 plus Notch4, and Jagged1 all
resulted in embryonic lethality related to vascular defects
[12, 13]. Mice homozygous for a single-point mutation at
the intramembranous processing site of Notch1 resembles
the null Notch1 phenotype, showing that Notch1 processing
is essential for embryonic viability and proper vascular mor-
phogenesis [14].
Both Delta-like 1 (Dll1) deﬁcient and Notch2-hypomor-
phic mice embryos presented with hemorrhage resulting
from poor development of vascular vessels [15, 16]. AlsoStem Cells International 3
Dll4+/− heterozygous mice exhibit embryonic lethal haploin-
suﬃciency because of vascular remodeling defects [17–19].
In human, the congenital cardiac malformation Alagille syn-
drome, an autosomal dominant disorder characterized by
developmental abnormalities, is caused by mutations of
Notch ligand JAGGED1 [20]. Another human disease,
CADASIL [21] (cerebral autosomal dominant arteriopathy
with subcortical infarct and leukoencephalopathy) is related
to a mutation of the Notch3 receptor [22]a n da ﬀects vas-
cular smooth muscle cell (VSMC) development.
3. Notch SignalingPathway inHematopoiesis
andHSCSelf-Renewal
During embryogenesis, ﬁrst the blood cells originate extra
embryonically within the embryonic yolk sac and later are
produced intra embryonically in the para-aortic splanchno-
pleura (P-sP) and aorta-gonad mesonephros (AGM). Subse-
quently, hematopoiesis takes place in the liver to ﬁnally shift
towards the spleen and bone marrow [23].
The analysis of mutant mice revealed that Notch signal-
ing is required during hematopoiesis. Hematopoietic cell
development was dramatically impaired in Notch1−/− em-
bryos, in which no HSC activity in P-sP and yolk sac was
detected. Although the mechanism of action is still poorly
understood, these observations unquestionably establish a
role for Notch1 in hematopoiesis [24]. In line with these
results, Notch cotranscription factor RBPjk mutant embryos
showed loss of hematopoietic precursors [24, 25]a n d
absence of GATA2, the transcription factor which is required
to maintain the hematopoietic precursor in an undiﬀeren-
tiated state [26]. GATA2 expression in the AGM hematopoi-
etic precursor appears to be regulated by Notch1 signaling
through the ligand Jagged1 and an RBPjk dependent path-
way. Consistently, mutant Jagged1 embryos were unable to
generated hematopoietic cells in the AGM [27].
In the adult, HSCs are mainly quiescent, however in re-
sponse to stress stimuli, they quickly regenerate damaged
hematopoietic cells through a process referred to as HSCs
self-renewal. Although Notch signaling together with Wnt
signaling has been indicated as a possible regulator of this
process [28], its role still remains controversial. Whereas loss
of function data do not support any role for Notch in adult
HSC, as shown by lack of eﬀects on HSCs after conditional
deletion of Notch1, Notch2, Jagged1 genes, or speciﬁc ex-
pression of a dominant negative mastermind in adult bone
marrow cells [29–31], gain of function data suggest a
role for Notch in HSCs self-renewal. Forced expression of
Notch1ICD in early c-Kit+/Sca1/+Lin- hematopoietic cells
(KLS)leadstoimmortalizationofthesecells[32].Ectopicex-
pression of Notch1IC also expanded the number of bone
marrow cells promoting their lymphoid diﬀerentiation over
myeloid lineage commitment [33] similar to Notch4IC
overexpression in Lin-cord blood cells [34].
Intravenous injection of cells expressing human Jagged1
into immune deﬁcient nonobese diabetic NOD/SCID mice
showed that Jagged1 was able to expand stem cells with
pluripotent capacity [35]. Similarly Varnum-Finney et al.
[36] have shown that stimulation of bone marrow precursor
with a Delta1 fusion protein resulted in inhibition of
myeloid diﬀerentiation while strongly increased the number
of precursor cells. In line with these results, retrovirus-
mediated transduction of CD34-KSL cells with Notch target
gene Hes1 preserves the long-term proliferation activity of
these cells [37]. Conversely, Notch inhibition by a dominant
RBPjk/CSLledtoaccelerateddiﬀerentiationofHSCsinvitro,
indicating that Notch is responsible for maintaining HSCs in
an undiﬀerentiated state [28].
4.Notch SignalingPathway andEPCsActivity
Although it is still a matter for debate, growing evidence in-
dicates that precursors of endothelial cells, EPCs, are respon-
sible for postnatal vascularization.
Asahara et al. [38] have isolated EPCs from bone marrow
(BM) and have shown that these cells play a role in induc-
ing vessel formation under physiological and pathological
conditions. EPCs are believed to reside in the BM together
with hematopoietic and hemangioblastic stem cells. EPCs
mobilization from BM would occur in response to ischemic
stimuli. Their subsequent recruitment at ischemic sites will
contribute to the formation of new blood vessels. In the BM
there are special microenvironments, so-called niches [39].
Osteoblasts, stromal cells, and ECs populate these niches
together with HSCs [40]. These niche cells express Notch
ligands such as Dll1 and Jagged1 [41–43]. The interaction
between osteoblasts presenting Notch ligands and HSCs
expressing Notch receptors is a key molecular mechanism
in the regulation of HSCs function in BM niche [36]. Thus,
it is possible that a similar mechanism would regulate the
function and recruitment of EPCs that reside in this niche.
Consistently, recent studies have shown a role for Notch
in EPC activity and postnatal vasculogenesis. Inhibition of
Notch has a negative eﬀect on revascularization via impair-
ment of EPC proliferation, diﬀerentiation, and mobilization
from BM [44]. Particularly, Notch ligand Jagged1 appears
to determine the diﬀerentiation of BM cells into EPCs. Loss
of Jagged1, but not of Dll1, resulted in reduced expression
of endothelial genes in BM cells and lower proliferative,
migratory and survival ability of BM-EPC-derived cells [44].
Consequently, Jagged1 deﬁcient BM cells showed reduced
capacity for vascular regeneration in ischemic tissue. Further
r e s e a r c ho nN o t c ha n di t sr o l ei nE P C sc o m m i t m e n t ,p r o l i f -
eration, and mobilization is required to fully understand its
importance during postnatal vasculogenesis.
5.Notch SignalingPathway duringEndothelial
SproutingAngiogenesis
Sprouting angiogenesis is an indispensable process during
growth of newly forming blood vessels. Sprouting is initiated
by the so-called tip cells that leave the conﬁnement of the
basal membrane and starts to spread ﬁlopodia into the
environment, thereby leading the way for the formation of
a new sprout. These tip cells are followed by stalk cells. In
this process, the role of Notch signaling is intertwined with4 Stem Cells International
another essential regulator of vascular development: vascular
endothelialgrowthfactor(VEGF)[45,46].Duringsprouting
angiogenesis, tip cells react to a VEGF gradient [47, 48]b y
migrating and extending ﬁlopodia. This response is highly
localized as the stalk cells—that follow the tip cell—already
respond diﬀerently to VEGF. Several recent studies have
shown the important role of Notch signaling in regulating
the formation and function of these tip cells. Endothelial
tip cells express high levels of VEGFR-2. In response to
VEGF stimulation, Dll4 expression is upregulated in these
cells. The selected tip cell expressing Dll4 interacts with
neighboring cells, thereby activating Notch signaling, which
in turn prevents migration and ﬁlopodia extension that will
functionally deﬁne these neighboring cells as stalk cells.
Thus, in the absence of Notch signaling, endothelial cells
continue to form sprouts in response to VEGF, resulting in
more sprouts and branches per blood vessel. This indeed
h a sb e e no b s e r v e di nd i ﬀerent model systems such as mouse
retina and hindbrain [17, 49–51], zebraﬁsh embryos [52,
53], and xenograft tumor models [51, 54, 55]. Consistently,
Dll4+/− mice [17, 49, 50] have serious vascular defects in the
retinal vasculature with excessive capillary density, diameter,
and ﬁlopodia extension of endothelial cells. Similar defects
have been observed with Notch inhibition, either in an
inducible Notch1 knockout [49], pharmacological blockade
by anti-Dll4 antibodies [50, 51], or γ-secretase inhibitors
[17,49].StalkcellsthatareuncheckedbyDll4alsoremained,
highly proliferative, as shown in Dll4 or RBP-Jk morphant
zebraﬁsh embryos [53].
The functional relationship between Notch signaling and
VEGF is clear. VEGF induces expression of Dll4 and Notch
signaling is required as well as suﬃcient for this eﬀect. Over-
expression of NICD-4 and NICD-1 eﬀectively transactivated
deletional fragments of the Dll4 promoter that contained
severalRBP-Jkbindingsites[56].AsADAMsmetalloprotein-
ase can mediate Notch signaling activation even in the abs-
ence of typical Notch ligands [57], it is possible that VEGFA-
induced ADAM activity results in enhanced Notch signaling,
with subsequent increase of Dll4 expression, and shut down
of VEGF signaling by VEGFR-2 shedding. Accordingly,
VEGF-induced Notch signaling and Dll4 expression was pre-
vented by ADAM blockers [56].
This two way relationship between VEGF and ADAM
activity could explain the spatial and/or temporal regulation
that causes the “salt and pepper” pattern of Dll4 expression
and associated tip and stalk cell distribution described for
the mouse retina model [49, 58]. Computational models,
supported by genetic mosaic sprouting assay such as time
laps microscopy analysis of chimaeric embryoid bodies,
have been used to allow various combinations of ECs
heterozygousforVEGFR1orVEGFR2tocompetewithwild-
type cells for the tip position [59–61]. Cells heterozygous
for VEGFR2 showed poor contribution to the tip cell pop-
ulation and predominantly became stalk cells, whereas cells
heterozygousforVEGFR1dominated thetip cellpopulation.
Thus, the balance of VEGFR2 and VEGFR1 expression in in-
dividual endothelial cells aﬀects their potential to become
tips cell during sprouting angiogenesis and this process
is mediated by Notch. In response to VEGF, cells which
are supposed to have high VEGFR-2 signal will upregulate
Dll4 and adopt tip cell position to initiate sprouting [59],
possibly in the initial absence of Notch ligands [57]D l l 4i n
turn triggers its own expression in a positive feed forward
fashion. Activated Notch downregulates VEGF signaling,
that might be the stop signal [62] to reduce sprouting in the
surrounding cells.
Although VEGFA, as the foremostVEGF family member,
has been indicated as major player in regulating sprouting
angiogenesis through VEGFR2 and upstream of Notch, a
recent study has suggested a role for VEGFC/VEGFR3 axis in
regulatingthisprocessaswell[63].VEGFR3appearstofunc-
tioninabimodalfashion.VEGFCexpressedbymacrophages
activates VEGFR3 in tip cells. Activated VEGFR3 in tip
cells subsequently contributes to sprouting by activating the
MAPK intracellular pathway. Concomitantly, VEGFR3 leads
to Notch activation ligand independent. Induced Notch sig-
naling will decrease the sensitivity of tip cells to a VEGF gra-
dient, participating to the conversion of tip cell to stalk cell
phenotype at fusion points of vessel sprouts and allowing the
growth of the newly forming vasculature.
6. Notch SignalingPathway inArterial
ECsSpeciﬁcation
Whereas Notch maintains HSCs in an undiﬀerentiated state,
its activation in the endothelium induces arterial/venous dif-
ferentiation. The importance of the Notch signaling pathway
in regulating arterial diﬀerentiation was initially shown in
Zebraﬁsh [64, 65] and later conﬁrmed in transgenic mouse
models [12, 19, 66–69] and in human endothelial cells [70].
In zebraﬁsh embryo, Notch signaling deﬁciency resulted
in a poorly formed dorsal aorta and posterior cardinal vein.
Arterial marker expression, such as EphrinB2, was low and
venous markers were ectopically expressed in the arterial
compartment. This expression pattern was similar to models
with reduced VEGFA signaling, whereas injection of VEGFA
mRNA gave a mirror image of expression of the arterial
marker EphrinB2 in the posterior cardinal vein [64]. More-
over, induced expression of Notch1 in VEGFA-deﬁcient em-
bryos rescued the expression of EphrinB2. In contrast,
VEGFA supplying into Notch signaling deﬁcient embryos
w a su n a b l et or e s t o r ea r t e r i a ld i ﬀerentiation [64].
In human cells, close interaction of VEGF and Notch sig-
naling in arterial diﬀerentiation has also been demonstrated.
Liu et al. [70] showed that Notch1 receptor and Dll4 ligand
are induced by VEGFA in human arterial but not in venous
endothelial cells. VEGF-A-induced Dll4, Notch4, EphrinB2
and downregulation of venous markers COUP-TFII and
EphB4 expression was also described for mouse embryonic
[71] and human bone-marrow-derived mesenchymal stem
cells [72]. Also ablation of the venous marker and repressor
of Notch signaling COUP-TFII in endothelial cells enabled
veins to express Notch signaling components, acquiring an
arterial phenotype, whereas COUP-TFII ectopic expression
resulted in fusion of arteries and veins (AV-shunts) in trans-








































Figure 2: Scheme showing the essential functions of Notch in blood and vascular cell types (a) Osteocyte Dll/Jag-induced Notch signaling
in hematopoietic stem cells (HSCs) is involved in their generation and self-renewal in the adult. (b) Notch signaling pathway is required for
endothelial progenitor cells (EPCs) development and function. EPCs from bone marrow niches will, in response to Notch, diﬀerentiate in
endothelialcells(ECs)andpopulatesitesofischemiaparticipatinginvascularization.(c)Schematicrepresentationofagrowingbloodvessel.
In angiogenesis, Notch ligand DLL4 is upregulated in response to VEGF/VEGFR2 signaling in tip cells, that are speciﬁed ECs (dark yellow)
capable of sprouting by extending ﬁlopodia. Upregulated DLL4 in tip cells activates Notch in the neighbor stalk ECs (light yellow) inhibiting
their sprouting capacity. Notch activation in stalk cells will result in further DLL4 upregulation, which eventually will activate Notch in
adjacent cells. SMCs, covering the endothelium are represented in green. (d) Notch induces arterial speciﬁcation of ECs by upregulating the
expression of arterial markers, such as EphrinB2. The lack of Notch in venous endothelial cells allows the expression of venous markers, such
as COUP-TFII. Notch regulates also smooth muscle cell (SMC) diﬀerentiation by inducing the expression of SMC-speciﬁc markers (e.g.,
αSMA, SM-MHC, SMα22, and SM calponin).
Occasionally surviving Dll4 heterozygous mice displayed
a lack of arterial markers in their vasculature, as do other
Notch signaling deﬁcient mice such as the RBP-Jk and Hey1
and Hey double-mutants. Studies in cultured endothelial
cells conﬁrmed that Dll4-induced Notch signaling upreg-
ulates EphrinB2 expression [74]. Furthermore, the overex-
pression of activated Notch4 (NICD-4) in adult mice was
also able to induce the expression of EphrinB2 in the venous
compartment. These mice were characterized by arteriove-
nous malformation that was reversible after repression of
Notch4 expression [75].
These studies provide evidence that both Notch and
VEGF are involved in a signaling cascade that is essential for
arterial-venous diﬀerentiation in which Notch signaling acts
downstream of the VEGF pathway.
7.Notch SignalingPathway in
vSMC Differentiation
Despite the common origin of hematopoietic cells and endo-
thelial cells, vascular SMCs come from a diﬀerent embry-
onic source. Lineage mapping studies have identiﬁed at
least eight independent possible SMC progenitors such
as neuronal crest, pericardium, mesothelium, secondary
heart ﬁeld, somites, mesoangioblasts, stem and progenitor
cells, microvascular SMCs, and perycites [76]. Intriguingly,
although all these progenitors have diﬀerent origin and
molecular characteristics, they all have the ability to diﬀeren-
tiateinacelltype,whichwillexpressSMCmarkergenessuch
as αSMActin (αSMA), SM-MHC (Smooth Muscle Myosin
Heavy Chain), SM22α, and SM-calponin. Subsequently,6 Stem Cells International
these SMCs diﬀerentiate further taking part to the formation
of either arterial or venous vessels.
The Notch signaling pathway plays a role in controlling
SMC fate speciﬁcation, although debates about the precise
role are still ongoing. Besides aﬀecting arterial ECs diﬀeren-
tiation, Notch signaling has been reported to specify arterial-
venous identity of vascular SMCs as well [77]. Among the
receptors, Notch3 is expressed in vascular SMCs from arter-
ies but not from veins [77]. Notch3−/− mice showed serious
arterial defects, such as enlarged arteries with a thinner
layer of SMCs [77] that were poorly diﬀerentiated [77, 78]
compared to wild-type animals. This is consistent with in
vitro data showing that ligand induced NOTCH signaling
upregulated the expression αSMA and SM-MHC promoting
VSMC diﬀerentiation [79, 80] via RBP-Jk. Among the
ligands, endothelial Jag1 appears to be essential in regulating
vascular morphogenesis by inducing Notch signaling in
the neighboring SMC. Endothelial-speciﬁc deletion of Jag1
causes serious cardiovascular abnormalities and embryonic
lethalityinmice[81].Surprisingly,theseembryosdiﬀerfrom
embryos in which general Notch signaling has been abro-
gated as they still present with normal Notch activation and
arterial diﬀerentiation of the endothelium. This suggests that
endothelial Jag1 mainly acts by inducing the diﬀerentiation
of the adjacent SMCs [81]. Notch3 activation by endothelial
Jag1 is further supported by enhanced expression of Notch3
in SMC cocultured with Jag1 expressing endothelial cells,
suggesting a positive feedback loop. Indeed, Liu et al. [80]
demonstrated that activated Notch3 signaling initiates a
positive feedback loop that promotes its own expression and
propagates Notch signaling to the other SMCs, meanwhile
inducing SMC diﬀerentiation markers, such as αSMA,
CALPONIN, and SM-MHC. These data are in contrast
with other studies in which Notch target genes have been
reported to antagonize SRF (serum response factor) and
myocardin, the main transcription regulators of VSMC gene
expressionandSMCdiﬀerentiation[82,83].Thecontroversy
between these reports might relate to the balance between
Notch ICD that induces the expression of VSMC markers
and the concomitant expression of Notch target genes such
as Hey1 and Hey2 that turn oﬀ these markers as part of
a negative feedback loop. The validity of this model has
been experimentally addressed by using ECs and SMC co-
cultures [83, 84]. Hey1 and Hey2 were indeed able to repress
αSMA expression and to antagonize Notch-induced αSMA
expression in vitro by decreasing Notch ICD/RBP-Jk binding
and transactivation of the αSMA promoter.
8. Conclusions
In this paper, we report on the essential role of the Notch
signaling pathway during embryonic vascular development
and postnatal neovascularization, with special focus on its
ability to aﬀect fate speciﬁcation of diﬀerent cell types.
Notch signaling appears to be indispensable early during
vasculogenesis by aﬀecting hematopoietic cell development.
This function is preserved in the adult during HSCs renewal,
and contributes to regenerate damaged hematopoietic cells
in response to stress stimuli (Figure 2(a)). Recently, a role
for Notch in controlling mobilization and diﬀerentiation of
EPCs from the BM niches has been reported. EPCs represent
an important therapeutic potential for vascular regenera-
tion, as they are able, in response to speciﬁc stimuli, to reach
ischemic sites and regenerate blood vessels (Figure 2(b)).
A more detailed understanding of Notch signaling mecha-
nism would certainly help to improve EPCs mediated neo-
vascularization following ischemia. Besides aﬀecting blood
cells generation and renewal, Notch signaling is implicated
in the diﬀerentiation of blood vessel cells such as ECs and
SMCs. Activation of Notch signaling is required for control-
ling sprouting angiogenesis of ECs, as its absence will re-
sult in excessive sprouting (Figure 2(c)). As a result, the
newly formed vascular network is not functional. Its role in
inducing arterial diﬀerentiation of endothelial and smooth
muscle cells has also received large attention. Notch acti-
vation determines whether a blood vessel will become an
artery or a vein, by inducing arterial and repressing venous
marker expression, respectively (Figure 2(d)).
Notch’s extraordinary ability to regulate speciﬁcation of
diﬀerentcelltypeswithinthevascularsystemmakesitapow-
erful therapeutic tool to target both pathological and physi-
ological vascularization.
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